With more targeted and effective therapies launching to treat a variety of cancers, much of the focus has been not only on their efficacy but their costs, particularly to payers. A recent report from the physician perspective highlights their impact as far as cost on not only those stakeholders but also the patients they serve.
- Abstract, Medicare and Medicaid
- Datapoint, Medicare and Medicaid
- Abstract, Specialty Pharmacy
- Datapoint, Drug Benefits
- Drug Benefits